Navigation Links
Heska Announces Q4 and Annual 2009 Results

LOVELAND, Colo., Feb. 22 /PRNewswire-FirstCall/ -- Heska Corporation ( HSKA, "Heska" or the "Company") today reported financial results for its fourth quarter and the year ended December 31, 2009.


"In the fourth quarter of 2009, we produced revenue growth in both of our operating segments, increased our gross margin and decreased our operating expenses compared to the fourth quarter of 2008.  For full year 2009, our team generated over $4 million in operating income – the second best result in company history, despite a challenging economic environment," said Robert Grieve, Heska's Chairman and CEO.  "We also placed our first DRI-CHEM® 7000 Veterinary Chemistry Analyzers with our customers in the fourth quarter of 2009.  We have been pleased with customer interest in this fine new product, which represents a line extension in our chemistry offering and is the fastest multi-patient clinical chemistry analyzer available to the veterinary in-clinic market.  We also are excited by the prospects for another new product in 2010, the VitalPath™ Blood Gas and Electrolyte Analyzer, which we expect to begin shipping to our customers in the near future."

Investor Conference Call

Management will conduct a conference call on Monday, February 22, 2010 at 1:00 p.m. MST (3:00 p.m. EST) to discuss the fourth quarter and year-end 2009 financial results.  To participate, dial (877) 941-2333 (domestic) or (480) 629-9723 (international); the conference call access number is 4218183.  The conference call will also be broadcast live over the Internet at  To listen, simply log on to the web at this address at least ten minutes prior to the start of the call to register, download and install any necessary audio software.  Telephone replays of the conference call will be available for playback until March 8, 2010.  The telephone replay may be accessed by dialing (800) 406-7325 (domestic) or (303) 590-3030 (international).  The webcast replay may be accessed from Heska's home page at until March 8, 2010.

About Heska

Heska Corporation (Nasdaq: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products.  Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines.  The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians.  For further information on Heska and its products, visit the company's website at

Forward-Looking Statements

This announcement contains forward-looking statements regarding Heska's future financial and operating results.  These statements are based on current expectations and are subject to a number of risks and uncertainties.  Investors should note that there is an inherent risk in using past results, including trends, to predict future outcomes.  In addition, factors that could affect the business and financial results of Heska generally include the following: uncertainties related to the access to products from Abbott Point of Care Inc. as of November 1, 2009, which represent approximately 15% of Heska's revenue for the year ended December 31, 2009, including the impact of the loss of related profits on Heska's year-over-year performance; risks inherent in relying on perceived initial customer interest to indicate future market acceptance and success of any given product; uncertainties related to product performance and market acceptance of any product planned, but not yet placed, with customers; risks related to any change in Heska's strategy, including Heska's recent decision to terminate its contractual agreements with most domestic third-party distributors who carry Heska's full product line, and the year-over-year and future impact of any such decision; uncertainties regarding Heska's reliance on third parties to whom Heska has granted substantial marketing rights to certain of Heska's existing products and whom may be large Heska customers; uncertainties regarding Heska's ability to successfully market and sell its products in an economically sustainable manner; risks related to Heska's reliance on third parties to properly and timely complete certain research and development activities; competition, including uncertainties regarding the impact of new products competitors have recently launched or may launch in the future; uncertainties related to Heska's ability to maintain its listing on the Nasdaq Capital Market; uncertainties regarding Heska's ability to generate profits and positive cash flow in future periods; risks regarding Heska's reliance on third-party suppliers, which is substantial and could have significant negative consequences if Heska were to lose access to a product line; uncertainties regarding overall economic conditions and the affect of these conditions on Heska's business, which may change as compared to historical results, as well as Heska's accuracy in predicting these and related matters; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Annual Report on Form 10-K for the year ended December 31, 2008 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2009.

Financial Table Follows:

                        Consolidated Statements of Operations
                        In Thousands, Except per Share Amounts
                                                Three Months   Twelve Months
                                                   Ended           Ended
                                                   -----           -----
                                                December 31,    December 31,
                                                ------------    ------------
                                               2008     2009    2008    2009
                                               ----     ----    ----    ----
    Revenue, net:
        Core companion animal health        $13,667  $14,541 $68,140 $66,449
        Other vaccines, pharmaceuticals
         and products                         1,767    2,817  13,513   9,229
                                              -----    -----  ------   -----
          Total revenue, net                 15,434   17,358  81,653  75,678
                                             ------   ------  ------  ------
    Cost of revenue                          11,093   10,723  52,809  47,219
                                             ------   ------  ------  ------
    Gross profit                              4,341    6,635  28,844  28,459
                                              -----    -----  ------  ------
    Operating expenses:
        Selling and marketing                 3,616    3,449  17,640  14,524
        Research and development                489      410   1,951   1,718
        General and administrative            2,161    1,918   8,917   8,173
        Restructuring expenses                  785        -     785       -
        Other                                   232        -     232       -
                                                ---      ---     ---     ---
             Total operating expenses         7,283    5,777  29,525  24,415
                                              -----    -----  ------  ------
    Operating income (loss)                  (2,942)     858    (681)  4,044
    Interest and other expense, net             140      113     640     306
                                                ---      ---     ---     ---
    Income (loss) before income taxes        (3,082)     745  (1,321)  3,738
    Income tax expense (benefit)             (1,215)     285    (471)  1,496
                                             ------      ---    ----   -----
    Net income (loss)                       $(1,867)    $460   $(850) $2,242
                                            =======     ====   =====  ======
    Basic net income (loss) per share        $(0.04)   $0.01  $(0.02)  $0.04
                                             ======    =====  ======   =====
    Diluted net income (loss) per share      $(0.04)   $0.01  $(0.02)  $0.04
                                             ======    =====  ======   =====
    Shares used for basic net income
     (loss) per share                        51,821   52,123  51,674  52,068
                                             ======   ======  ======  ======
    Shares used for diluted net income
     (loss) per share                        51,821   52,199  51,674  52,115
                                             ======   ======  ======  ======
                               Balance Sheet Data
                             In Thousands (unaudited)
                                                December 31,    December 31,
                                                   2008            2009
                                                   ----            ----
    Cash and cash equivalents                     $4,705          $5,400
    Total current assets                          31,290          28,493
    Total assets                                  70,438          64,134
    Line of credit                                11,042           4,201
    Current portion of long-term debt                770             381
    Total current liabilities                     22,228          14,107
    Long-term debt, net of current portion           381               -
    Stockholders' equity                          42,523          45,055

SOURCE Heska Corporation

Back to top



SOURCE Heska Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Heska Announces Installation of New Chemistry Analyzer
2. Webcast Alert: Heska Announces Second Quarter 2009 Earnings Conference Call Webcast
3. Heska Announces Q109 Results
4. Webcast Alert: Heska Corporations Annual Meeting of Stockholders Webcast
5. Heska Announces Q4 and Annual 2008 Results
6. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast
7. Heska to Present at New York Society of Security Analysts 12th Annual Biotech and Specialty Pharma Conference
8. Heska Announces Q3 2008 Results
9. Webcast Alert: Heska Announces Third Quarter 2008 Earnings Conference Call Webcast
10. Deloitte Names Heska Corporation to Colorado Technology Fast 50
11. Webcast Alert: Heska Announces First Quarter 2008 Earnings Conference Call Webcast
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken ... for accurate interpretation by the radiologist. The marking utensils are so small, however, ... has found a way to alleviate this problem. , He developed the patent-pending ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates ... a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they ... Society of North America (RSNA) 2015 annual meeting through December 3 in Chicago, ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
(Date:12/1/2015)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing ... that the company will present at the LD Micro Main ... Luxe Sunset Boulevard Hotel in Los Angeles, CA. ... will present on Thursday, December 3, at 9:00 am Pacific ... register at least 10 minutes prior to the start of ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology: